Omnicell (NASDAQ:OMCL) Price Target Lowered to $38.00 at Wells Fargo & Company

Omnicell (NASDAQ:OMCL) had its price objective decreased by investment analysts at Wells Fargo & Company from $40.00 to $38.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Wells Fargo & Company‘s price target points to a potential upside of 25.50% from the company’s current price.

Several other brokerages have also recently issued reports on OMCL. Benchmark restated a “buy” rating and issued a $62.00 target price on shares of Omnicell in a report on Tuesday, February 4th. JPMorgan Chase & Co. decreased their price objective on shares of Omnicell from $44.00 to $36.00 and set a “neutral” rating for the company in a research note on Thursday, March 20th. StockNews.com upgraded Omnicell from a “hold” rating to a “buy” rating in a research report on Tuesday. Finally, Bank of America decreased their target price on Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a research report on Monday, January 6th. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $50.67.

Omnicell Price Performance

Omnicell stock opened at $30.28 on Thursday. The stock has a market cap of $1.42 billion, a P/E ratio of 112.15, a price-to-earnings-growth ratio of 7.53 and a beta of 0.78. The company has a fifty day simple moving average of $35.27 and a 200-day simple moving average of $41.27. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 0.13. Omnicell has a 12-month low of $25.12 and a 12-month high of $55.75.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings data on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. Equities analysts expect that Omnicell will post 1.09 EPS for the current fiscal year.

Institutional Investors Weigh In On Omnicell

Several hedge funds have recently made changes to their positions in the business. Smartleaf Asset Management LLC increased its position in Omnicell by 51.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 803 shares of the company’s stock valued at $35,000 after acquiring an additional 273 shares during the period. Johnson Financial Group Inc. acquired a new position in shares of Omnicell in the fourth quarter valued at approximately $37,000. Van ECK Associates Corp raised its stake in shares of Omnicell by 47.0% during the fourth quarter. Van ECK Associates Corp now owns 985 shares of the company’s stock worth $44,000 after purchasing an additional 315 shares during the last quarter. Headlands Technologies LLC acquired a new stake in shares of Omnicell during the fourth quarter worth $53,000. Finally, First Horizon Advisors Inc. grew its position in Omnicell by 36.3% in the 4th quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company’s stock valued at $59,000 after buying an additional 355 shares during the last quarter. Institutional investors and hedge funds own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.